"4"^^ . "Altered phosphorylation of cellular proteins stimulated an extensive search for protein kinase inhibitors as drugs. Cyclin-dependent kinases (CDKs), enzymes involved in diverse cellular processes, including cell division cycle, transcription, differentiation and apoptosis, are suitable targets of such inhibitors with potential application in cancer therapy1. One of the first reported specific CDK inhibitors, olomoucine, had became a leading compound of the development based on structure-activity relatioships, that led to the synthesis of roscovitine2 and olomoucine II (ref.3), respectively. Both derivatives show an enhanced CDK inhibitory activity, increased selectivity and antiproliferative activity. Moreover, roscovitine has been also shown to induce nuclear accumulation of tumour suppressor p53 and enhance p53-dependent transcription in human cancer cells4. The novel derivative olomoucine II inhibits CDKs more efficiently and causes cell cycle blocks at G1/S and G2/M transitions stronger than rosc"@en . . . "RIV/61989592:15310/04:00002152!RIV/2005/MSM/153105/N" . "RIV/61989592:15310/04:00002152" . . "Otyepka, Michal" . "CDK;inhibitor;p53;anticancer drug"@en . . "278"^^ . "Ors\u00E1g, Martin" . "Zm\u011Bn\u011Bn\u00E1 fosforylace bun\u011B\u010Dn\u00FDch protein\u016F v n\u00E1dorov\u00FDch bu\u0148k\u00E1ch vyvolala z\u00E1jem o inhibitory proteinkinas jako potenci\u00E1ln\u00ED l\u00E9\u010Diva. Cyklin-dependentn\u00ED kinasy (CDK), kter\u00E9 \u0159\u00EDd\u00ED r\u016Fzn\u00E9 bun\u011B\u010Dn\u00E9 procesy od bun\u011B\u010Dn\u00E9ho cyklu, p\u0159es transkripci, diferenciaci a apopt\u00F3zu, pat\u0159\u00ED ovn\u011B\u017E mezi farmakologick\u00E9 zaj\u00EDmav\u00E9 c\u00EDle. Jeden z prvn\u00EDch specifick\u00FDch inhibitor\u016F CDK olomoucin se stal v\u00FDchoz\u00EDm bodem pro v\u00FDvoj \u00FA\u010Dinn\u011Bj\u0161\u00EDch inhibitor\u016F, nap\u0159. roskovitinu anebo olomoucinu II. Ob\u011B tyto l\u00E1tky ji\u017E vykazuj\u00ED vysokou \u00FA\u010Dinnost a specifitu. Roskovitin nav\u00EDc indukuje akumulaci n\u00E1dorov\u00E9ho supresoru p53 v j\u00E1d\u0159e a podporuje jeho transkrip\u010Dn\u00ED aktivitu. Nov\u00FD inhibitor olomoucin II pak pat\u0159\u00ED k je\u011Bt\u011B \u00FA\u010Dinn\u011Bj\u0161\u00EDm inhibitor\u016Fm bun\u011B\u010Dn\u00E9 proliferace. Na\u0161e v\u00FDsledky potvruj\u00ED, \u017Ee antiprolifera\u010Dn\u00ED aktivita inhibitor\u016F CDK je zp\u016Fsobena p\u0159\u00EDmou inhibic\u00ED CDK a indukc\u00ED p53, co\u017E vyzdvihuje mo\u017En\u00E9 farmakologick\u00E9 aplikace inhibitor\u016F CDK."@cs . "CZ - \u010Cesk\u00E1 republika" . . "Antiproliferative activity of Olomoucine II, a novel cyclin-dependent kinase inhibitor" . "Antiproliferativn\u00ED \u00FA\u010Dinky nov\u00E9ho inhibitoru CDK, olomoucinu II"@cs . "15310" . . "Acta Universitatis Palackianae Olomucensis, Facultas Rerum Naturalium, Chemica" . "Antiproliferative activity of Olomoucine II, a novel cyclin-dependent kinase inhibitor"@en . "43" . . . "133" . . . . . . . "5"^^ . "Vojt\u011B\u0161ek, Bo\u0159ivoj" . "Antiproliferative activity of Olomoucine II, a novel cyclin-dependent kinase inhibitor" . "Z(MSM 153100008)" . "554842" . "[FED9727C0065]" . . "Strnad, Miroslav" . . "Suppl." . "Altered phosphorylation of cellular proteins stimulated an extensive search for protein kinase inhibitors as drugs. Cyclin-dependent kinases (CDKs), enzymes involved in diverse cellular processes, including cell division cycle, transcription, differentiation and apoptosis, are suitable targets of such inhibitors with potential application in cancer therapy1. One of the first reported specific CDK inhibitors, olomoucine, had became a leading compound of the development based on structure-activity relatioships, that led to the synthesis of roscovitine2 and olomoucine II (ref.3), respectively. Both derivatives show an enhanced CDK inhibitory activity, increased selectivity and antiproliferative activity. Moreover, roscovitine has been also shown to induce nuclear accumulation of tumour suppressor p53 and enhance p53-dependent transcription in human cancer cells4. The novel derivative olomoucine II inhibits CDKs more efficiently and causes cell cycle blocks at G1/S and G2/M transitions stronger than rosc" . "Kry\u0161tof, Vladim\u00EDr" . . "Antiproliferativn\u00ED \u00FA\u010Dinky nov\u00E9ho inhibitoru CDK, olomoucinu II"@cs . "0232-0061" . . "Antiproliferative activity of Olomoucine II, a novel cyclin-dependent kinase inhibitor"@en . .